1 A Novel Susceptibility Locus in NFASC Highlights Oligodendrocytes and

2 <u>Myelination in Progressive Supranuclear Palsy Pathology</u>

- **Pablo García-González^{1,2,3}**, Héctor Rodrigo Lara⁴, Yaroslau Compta^{5,6}, Manuel
- 4 Fernandez^{5,6}, Sven J. van der Lee^{7,8,9}, Itziar de Rojas^{1,2}, Laura Saiz¹⁰, Celia Painous^{5,6},
- 5 Ana Camara^{5,6}, Esteban Muñoz^{5,6}, Maria J. Marti^{5,6}, Francesc Valldeoriola^{5,6}, Raquel
- 6 Puerta^{1,3}, Ignacio Illán-Gala^{11,2}, Javier Pagonabarraga^{12,2}, Oriol Dols-Icardo^{11,2}, Jaime
- 7 Kulisevsky^{12,2}, Juan Fortea^{11,2}, Alberto Lleó^{11,2}, Claudia Olivé¹, Sterre C.M. de
- 8 Boer^{13,9,14}, Marc Hulsman^{7,8,9}, Yolande A.L. Pijnenburg^{8,9}, Rafael Díaz Belloso^{15,16},
- 9 Laura Muñoz-Delgado^{15,16}, Dolores Buiza Rueda^{15,16}, Pilar Gómez-Garre^{15,16}, Iban
- 10 Aldecoa^{17,18}, Gemma Aragonés¹⁷, Jorge Hernandez Vara^{19,16}, Maite Mendioroz^{20,21,22},
- 11 Jordi Pérez-Tur^{23,2}, Pieter Jelle Visser^{24,25,26,27}, Anouk den Braber^{24,25,28}, Janne M.
- 12 Papma^{29,30}, Ángel Martín Montes^{2,31,32}, Eloy Rodriguez-Rodriguez^{33,2}, Josep Blázquez-
- 13 Folch¹, Andrea Miguel¹, Fernando García-Gutiérrez¹, Amanda Cano^{1,2}, Sergi Valero^{1,2},
- 14 Marta Marquié^{1,2}, María Capdevila-Bayo^{1,34}, Maitee Rosende-Roca³⁵, Inés Quintela³⁶,
- 15 Ángel Carracedo^{37,38}, Lluís Tàrraga^{1,2}, Luis M Real^{39,40}, Jose Luis Royo⁴¹, Maria Elena
- 16 Erro^{42,43}, Carmen Guerrero⁴⁴, Daniela Corte Torres⁴⁵, Marta Blázquez-Estrada^{46,47}
- Beatriz San Millán^{48,49}, Susana Teijeira^{48,50}, Dolores Vilas Rolan⁵¹, Isabel Hernández^{1,2}
- Antonio Sánchez-Soblechero⁵², Beatriz de la Casa-Fages⁵³, Soledad Serrano López^{31,32},
- 19 Raquel Baviera-Muñoz⁵⁴, Amaya Lavín⁵⁵, Ricardo Taipa^{56,57}, Guillermo Amer⁵⁸, Elena
- 20 Martinez-Saez^{59,60}, Marta Fernández-Matarrubia^{61,62}, Carmen Lage-Martínez^{63,2,64},
- Victoria Álvarez^{65,47}, Laura Molina-Porcel^{66,17}, Henne Holstege^{7,8,9}, Pablo Mir^{15,16,67},
- Victoria Arvaicz , Laura Monna-Forcer , Heine Horstege , Faoto Mil
 Olivia Belbin^{68,2}, Mercè Boada^{1,2}, Victoria Fernández¹, María J. Bullido^{69,2,31,70},
- Alberto Rábano^{71,2}, Pascual Sánchez-Juan^{71,2}, Agustín Ruiz^{1,2,72*}

24 * Corresponding author: Agustín Ruiz MD, PhD.

25 María J. Bullido, Alberto Rábano, Pascual Sánchez-Juan and Agustín Ruiz contributed equally to this work.

¹Ace Alzheimer Center Barcelona-Universitat Internacional de Catalunya, Barcelona, Spain,

²CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National
 Institute of Health Carlos III, Madrid, Spain, ³Universitat de Barcelona (UB), Barcelona, Spain, ⁴Banco

de Cerebros de la Región de Murcia, Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar,

- 30 Spain, ⁵Parkinson's Disease & Movement Disorders Unit, Neurology Service, Hospital Clínic I
- Universitari de Barcelona; IDIBAPS, CIBERNED (CB06/05/0018-ISCIII), ERN- RND, Institut Clínic de
- 32 Neurociències (Maria de Maeztu Excellence Centre), Universitat de Barcelona. Barcelona, Catalonia,
- 33 Spain, ⁶Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders: Clinical and
- 34 Experimental Research; Department of Neurology, Hospital Clínic de Barcelona, Institut
- 35 D'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Institut de Neurociències, Universitat de
- 36 Barcelona, Barcelona, Catalonia, Spain, ⁷Genomics of Neurodegenerative Diseases and Aging, Human
- 37 Genetics, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The
- 38 Netherlands., ⁸Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam
- **39** UMC location VUmc, Amsterdam, The Netherlands ., ⁹Amsterdam Neuroscience, Neurodegeneration,
- 40 Amsterdam, The Netherlands, ¹⁰Alzheimer's Disease Research Unit, CIEN Foundation, Queen Sofia
- Foundation Alzheimer Center, Madrid, Spain, ¹¹Sant Pau Memory Unit, Department of Neurology,
 Institut de Recerca de Sant Pau; Hospital de Sant Pau, Barcelona, Spain, ¹²Movement Disorders Unit,
- Institut de Recerca de Sant Pau; Hospital de Sant Pau, Barcelona, Spain, ¹²Movement Disorders Unit
 Department of Neurology, Institut de Recerca de Sant Pau; Hospital de Sant Pau, Barcelona, Spain,
- 43 Department of Neurology, Institut de Recerca de Sant Pau; Hospital de Sant Pau, Barcelona, Spain,
 44 ¹³Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location
- 44 VUmc, Amsterdam, The Netherlands., ¹⁴School of Psychology and Brain & Mind Centre, The University
- 46 of Sydney, Sydney, Australia, ¹⁵Unidad de Trastornos del Movimiento, Servicio de Neurología y
- 46 of Sydney, Sydney, Austrana, "Unidad de Trastornos del Movimiento, Servicio de Neurología y
 47 Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, IBiS / Hospital Universitario Virgen del
- 47 Neuronsiologia Chinca, instituto de Biomedicina de Sevina, IBIS / Hospital Oniversitano virgen dei 48 NORE Juis OSPON Centre neuroratione de Biomedicina de Sevina, IBIS / Hospital Oniversitano virgen dei

49 Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain., 50 ¹⁷Neurological Tissue Bank, Biobanc-Hospital Clínic-FRCB-IDIBAPS, Barcelona, Spain., ¹⁸Pathology 51 Department, Hospital Clinic de Barcelona-University of Barcelona, Barcelona, Spain, ¹⁹Servicio de 52 Neurologia y Grupo de Enfermedades Neurodegenerativas. Vall d'Hebron Institut de Recerca (VHIR), 53 Barcelona, Spain, ²⁰Navarrabiomed, Pamplona, Spain, ²¹Department of Neurology, Hospital Universitario 54 de Navarra, Pamplona, Spain, ²²Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, 55 Spain, ²³Unitat de Genètica Molecular, Institut de Biomedicina de València-CSIC, Valencia, Spain, 56 ²⁴Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location 57 VUmc, Amsterdam, The Netherlands, ²⁵Amsterdam Neuroscience, Neurodegeneration, 1081 HV 58 Amsterdam, The Netherlands, ²⁶Alzheimer Center Limburg, School for Mental Health and Neuroscience, 59 Maastricht University, 6200 MD Maastricht, The Netherlands, ²⁷Department of Neurobiology, Care 60 Sciences and Society, Division of Neurogeriatrics, Karolinska Institutet, 171 77 Stockholm, Sweden, 61 ²⁸Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, 405 30 Gothenburg, Sweden, ²⁹Department of 62 63 Neurology and Alzheimer Center Erasmus MC, Erasmus MC University Medical Center, Rotterdam, the 64 Netherlands, ³⁰Department of Internal Medicine Erasmus MC, Erasmus MC University Medical Center, 65 Rotterdam, the Netherlands, ³¹Hospital La Paz Institute for Health Research, IdiPAZ, Madrid, Spain, 66 ³²Department of Neurology, La Paz University Hospital, Madrid, Spain, ³³Neurology Service, Marqués de 67 Valdecilla University Hospital (University of Cantabria and IDIVAL), Santander, Spain, ³⁴Department of 68 Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Science, 69 Universitat de Barcelona, Spain, ³⁵Ace Alzheimer Center Barcelona, Universitat Internacional de 70 Catalunya, Barcelona, Spain, ³⁶Grupo de Medicina Xenómica, Fundación Pública Galega de Medicina Xenómica, Santiago de Compostela, Spain, ³⁷Grupo de Medicina Xenómica, CIBERER, CIMUS. 71 72 Universidade de Santiago de Compostela, Santiago de Compostela, Spain, ³⁸Fundación Pública Galega de Medicina Xenómica- IDIS, Santiago de Compostela, Spain, ³⁹Instituto de Biomedicina de Sevilla, 73 74 IBiS/Hospital Universitario Virgen de Valme /CSIC/Universidad de Sevilla. Departamento de Bioqímica 75 Médica, Biología Molecular e Inmunología. Sevilla, Spain, ⁴⁰CIBERINFEC, Network Center for 76 Biomedical Research in Infectious Diseases, National Institute of Health of Carlos III, Madrid, Spain, 77 ⁴¹Departamento de Especialiaddes Quirurgicas, Bioquimica e Inmunologia, Facultad de Medicina, 78 Universidad de Malaga, Malaga, Spain, ⁴²Servicio de Neurología, Hospital Universitario de Navarra, 79 Pamplona, Spain, ⁴³Grupo de investigación Neuroepigenética, Navarrabiomed, Pamplona, Spain, ⁴⁴Banco 80 de Cerebros (Biobanco), Hospital Universitario Fundación Alcorcón, 28922 Alcorcón, Spain, ⁴⁵Biobank 81 of Principado de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, 82 Spain, ⁴⁶Servicio de Neurología, Hospital Universitario Central de Asturias, Spain, ⁴⁷Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), ⁴⁸Rare Diseases and Pediatric Medicine 83 84 Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Hospital 85 Álvaro Cunqueiro, 36312 Vigo, Spain, ⁴⁹Pathology Department, Galicia Sur Health Research Institute 86 (IIS Galicia Sur). SERGAS-UVIGO. Alvaro Cunqueiro Hospital, Vigo, Spain, ⁵⁰Biobank of Galicia Sur 87 Health Research Institute (Biobank IIS Galicia Sur), SERGAS-UVIGO, Hospital Álvaro Cunqueiro, 88 36312 Vigo, Spain, ⁵¹Movement Disorders Unit, Neurology Service, Hospital Germans Trias i Pujol, 89 Badalona, Barcelona, Spain, ⁵²Department of Neurology, Instituto de Investigación Sanitaria Gregorio 90 Marañón, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁵³Movement Disorders Unit, 91 Neurology Department, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General 92 Universitario Gregorio Marañón, Madrid, Spain, ⁵⁴Molecular, Cellular and Genomics Biomedicine 93 Research Group. Instituto de Investigación Sanitaria La Fe, Valencia, Spain, ⁵⁵Navarrabiomed, Hospital 94 Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), IdiSNA, Pamplona, Spain, 95 ⁵⁶Department of Neuropathology, Centro Hospitalar Universitário de Santo António, Porto, Portugal, 96 ⁵⁷UMIB - Unit for Multidisciplinary Research in Biomedicine, ICBAS - School of Medicine and 97 Biomedical Sciences, University of Porto, 4050-313, Porto, Portugal, ⁵⁸Cognitive Neurology Unit, Son 98 Espases University Hospital, Palma, Spain, ⁵⁹Pathology Department, Neuropathology. Vall d'Hebron University Hospital, Barcelona, Spain, ⁶⁰Vall d'Hebron University Hospital Biobank, Vall d'Hebron 99 100 Hospital Research Institute, Barcelona, Spain, ⁶¹Department of Neurology, Clínica Universidad de 101 Navarra, Pamplona, Spain, ⁶²IdiSNA, Navarra Institute for Health Research, Pamplona, Spain, 102 ⁶³Neurology Service, Marqués de Valdecilla University Hospital-IDIVAL, Santander, Spain, ⁶⁴dAtlantic 103 Fellow for Equity in Brain health, Global Brain Health Institute, University of California, San Francisco, 104 United States, 65 Laboratorio de Genética. Hospital Universitario Central de Asturias, Oviedo, Spain,

105 ⁶⁶Alzheimer's disease and other cognitive disorders unit. Neurology Service, Hospital Clínic, Fundació de

106 Recerca Clínic Barcelona-Institut d'Investigacions Biomediques August Pi i Sunyer (FRCB-IDIBAPS),

107 University of Barcelona, Barcelona, Spain, ⁶⁷Departamento de Medicina, Facultad de Medicina,

108 Universidad de Sevilla, Spain, ⁶⁸Department of Neurology, II B Sant Pau, Hospital de la Santa Creu i Sant

Pau, Universitat Autònoma de Barcelona, Barcelona, Spain, ⁶⁹Centro de Biología Molecular Severo
 Ochoa (UAM-CSIC), ⁷⁰Universidad Autónoma de Madrid, ⁷¹Alzheimer's Centre Reina Sofia-CIEN

Foundation-ISCIII, 28031 Madrid, Spain, ⁷²Glenn Biggs Institute for Alzheimer's & Neurodegenerative

112 Diseases, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

113 Abstract

114 We conducted the largest PSP GWAS of the Iberian population to date (522 cases from 22

115 Spanish and Portuguese institutions). We independently replicated seven known PSP risk

116 variants, and unveiled a novel locus in *NFASC/CNTN2* after meta-analysing our results with

a newly available Dutch cohort and publicly available summary statistics. These findings

118 highlight the importance of neuron-oligodendrocyte interactions in PSP etiopathology.

119 **Main**

120 Progressive supranuclear palsy (PSP) is a proteinopathy neuropathologically defined by intra-121 neuronal and intra-glial aggregations of 4-repeat microtubule associated tau and clinically 122 expressed as several phenotypes with different combinations of oculomotor, parkinsonian, bulbar, 123 cognitive, and behavioural features¹. The common allele of an ancestral 900 kb inversion, known 124 as the MAPT H1 haplotype, is the most important genetic risk factor for sporadic PSP, causing a 125 5.5-fold increase in PSP risk compared to the alternative MAPT H2 haplotype². Importantly, the low prevalence of PSP conditions the scarcity of genome-wide association studies (GWAS), with 126 only eight genetic risk loci reported to date³⁻⁵. Elucidating the genetic component of PSP could 127 128 lead to early and improved diagnosis, identification of pathophysiological biomarkers and novel 129 therapeutic treatments.

130 The PSP/DEGESCO cohort consists of clinical (N=327) and histopathological (N=195) PSP 131 subjects from Spain and Portugal (Supplementary Table 1), genotyped using the Affymetrix 815K Spanish (Thermo Fisher). We leveraged our previous cohort, 132 Biobank Array 133 GR@ACE/DEGESCO⁶, to select our controls (N=1950). Since cases and controls were 134 genotyped by the same platform and sequencing centre, we performed joint calling, quality control (QC) and TOPMed imputation⁷ of our genomic data, following standard procedures 135 (Supplementary Information, Extended data Fig. 1). Clinical cases fulfilling the Movement 136 137 Disorder Society (MDS) criteria for probable PSP⁸ were initially selected for our study, allowing 138 the inclusion of atypical PSP phenotypes. However, we observed that atypical cases had a 139 decreased MAPT H1 burden compared to those with histopathological confirmation ($\chi^2=6.29$; 140 DF=1; p=0.01), and that other known PSP genetic risk factors also showed weaker associations 141 with disease status in atypical cases compared to those with Richardson's syndrome (PSP-RS) or

histopathological confirmation (Supplementary Information), indicating the presence of
 phenotypic heterogeneity in our non-Richardson clinical cases (nR-PSP). As increasing the
 sample size in detriment of phenotypic accuracy can undermine the detection of small effect
 variants in GWAS studies⁹, we decided to keep only PSP-RS and histopathologically confirmed
 cases for further analysis.

147 We ran PC-adjusted case-control genome wide associations (~9M common genetic variants) for 148 our three subcohorts of Spanish and Portuguese ancestry (Extended Data Table 2), and meta-149 analyzed these results using a common effects inverse variance-weighed fixed-effect approach. 150 We detected a strong genome-wide significant (GWS) signal (Fig. 1) for the well-known PSPrisk MAPT H1 haplotype (rs8070723 A: OR[95%CI]=4.02[3.12-5.19]; p=9.89.10⁻²⁷), and 151 152 replicated six additional PSP susceptibility loci in our study, showing consistent effect directions with previous reports (Extended Data Table 3): MOBP (rs1768208 G: OR/95%CI]=0.76[0.64-153 0.89]; p=2.49·10⁻⁰⁴), EIF2AK3 (rs7571971 C: OR[95%CI]=0.80[0.68–0.95]; p=9.06·10⁻⁰³), STX6 154 155 *OR*[*95%CI*]=0.84[0.71–0.98]; *p*=0.03), SLCO1A2 (rs1411478 G: (rs11568563 A: *OR*[*95%CI*]=0.54[0.42–0.69]; $p=1.17\cdot 10^{-06}$), 156 and DUSP10 (rs6687758 A: OR[95%CI]=0.80[0.66-0.97]; p=0.02). After adjusting by the MAPT H1 haplotypic background, 157 158 we also reproduced an additional independent signal within the MAPT locus, which partially tags the PSP risk H1c subhaplotype, (rs242557 G: OR[95%CI]=0.72[0.61-0.86]; $p=2.49\cdot10^{-04}$). 159 160 However, the effect of the GWS *RUNX2 locus*, reported by Chen *et al.*⁵, was not significant in 161 our analysis (rs6458446 A: OR/95%CI]=0.90[0.75–1.09]; p=0.27). Additionally, a recent preprint study¹⁰ reported a GWS signal in the APOE locus where APOE ɛ4 was the protective 162 163 allele and APOE ε 2 was the risk allele. In our study, we replicated the described APOE ε 4 164 protective effect (rs429358 C: OR/95%CI)=0.72[0.53–0.96]; p=0.02), but APOE ε^2 was not significant (rs7412 T: OR[95%CI]=1.08[0.78–1.49]; p=0.64). Whether a protective mechanism 165 166 for APOE £4, the most important genetic risk factor for sporadic AD, exists in PSP, or this effect 167 is caused by a selection bias favouring inclusion of cases without amyloid pathology needs to be clearly stablished in future studies. Finally, the TNXB/C4A locus, described by another recent 168 169 preprint article¹¹, was not replicated (rs369580 G: OR/95% CI]=1.25[0.86–1.82]; p=0.24), 170 although its effect direction was concordant in our cohort.

Aiming to find novel PSP associations, we conducted a meta-analysis of our Spanish and Portuguese cohort with the results of the Sanchez-Contreras *et al.* study⁴, the largest publicly available summary statistics for PSP genetics, and an additional dataset including 59 clinical PSP-RS subjects and 1513 controls provided by the Amsterdam Dementia Cohort, totally comprising 3099 PSP and 11482 controls (Extended Data Table 4). An important limitation of this approach was that, due to the design of the previous studies^{3,4}, only 36 SNPs were available for metaanalysis. We found a novel GWS association of the *NFASC* locus (rs12744678 C: *OR[95%*

CI=0.83[0.78–0.89]; p=4.15·10⁻⁰⁸), which had null heterogeneity across cohorts (I²=0%), and 178 179 showed concordant effect directions in all groups (Fig. 2, Extended Data Table 5). The NFASC gene encodes the neurofascin proteins and is highly expressed by neurons and oligodendrocytes. 180 181 These proteins are involved in the development of axon initial segments and nodes of Ranvier in 182 the central (CNS) and peripheral nervous system (PNS) by forming paranodal junctions, a very 183 specialized cell-cell adhesion complex that is essential for correct myelination and impulse 184 conduction^{12,13}. Moreover, mutations in NFASC have been linked to neurodevelopmental 185 disorders with central and peripheral motor dysfunction [61], and anti-neurofascin antibodies are 186 found in a fraction of patients with CNS and PNS demyelinating diseases, such as multiple sclerosis¹⁴. Interestingly, although we did not find any significant QTLs for this variant, we found 187 that rs4951151, the top variant on the locus (Fig. 2), is an eQTL for the neighbouring gene CNTN2 188 in cerebellar tissue (on GTEx https://gtexportal.org/), and a pQTL for CNTN2 in CSF and plasma 189 (1:205001174-T-C, on ONTIME https://ontime.wustl.edu/)¹⁵. Importantly, CNTN2 is almost 190 exclusively expressed by oligodendrocytes and is highly coexpressed with MOBP and SLCO1A2, 191 two known PSP susceptibility loci (Extended Data Fig. 3). These three genes belong to the same 192 193 expression cluster, which is implicated in myelination and enriched in this specific cell type 194 (Extended Data Fig. 3). CNTN2 encodes contactin-2 a transmembrane protein also implicated in 195 the organization of nodes of Ranvier at the juxtaparanodal junctions. A study observed that the 196 absence of this protein can impair oligodendrocyte function and axonal conduction, although it 197 did not affect myelination under pathological conditions¹⁶.

198 The finding of the novel NFASC/CNTN2 locus, along with other replicated loci, such as MOBP, 199 SLCO1A2 and DUSP10, highlight the importance of myelination and oligodendrocyte-neuron 200 interactions in PSP etiopathology: MOBP encodes the myelin-associated oligodendrocyte basic 201 protein, a vital protein for myelin sheath structural integrity and maintenance in the central 202 nervous system, SLCO1A2 is highly expressed in the brain, almost exclusively by 203 oligodendrocytes, and is highly correlated to the oligodendrocytes myelination expression 204 cluster¹⁷, and *DUSP10* is highly expressed in oligodendrocytes and inhibitory neurons, encoding 205 a phosphatase involved in MAP kinases inactivation which is able to induce oligodendrocyte 206 differentiation (Extended Data Fig. 4)¹⁸. Gene ontology enrichment, including the PSP genes we 207 replicated and the novel NFASC locus, reveals biological features related to myelination and axon 208 ensheathment (Extended Data Table 6). Moreover, coexpression network analysis revealed that 209 MARK1, encoding the microtubule affinity regulating kinase 1, a kinase capable of phosphorylating tau promoting microtubule destabilisation¹⁹, is highly coexpressed with *MOBP*, 210 211 SLCO1A2 and NFASC (Extended Data Fig. 5). Furthermore, a recent, preprint GWAS has also 212 found that several PSP risk variants have oligodendrocyte-specific effects on gene expression¹¹. 213 Oligodendrocytes have a prominent microtubule structure and express *tau*, which plays a role in

214 early contact initiation in axons, maintaining microtubule stability and myelination²⁰. Moreover, 215 tau pathology, which is predominantly neuronal in AD, is commonly found in white matter oligodendrocytes in PSP and other tauopathies²⁰, and deregulation of myelination processes has 216 been linked to neurodegenerative diseases, with a special emphasis on PSP²¹. Overall, genetic 217 218 findings suggest that oligodendrocyte dysfunction and impaired myelination may play a 219 significant role in the etiopathogenesis of PSP. Additionally, there is increasing evidence 220 suggesting astrocytic tau pathology occurs in the earliest stages of corticobasal degeneration and PSP^{22,23}. This points to a paradigm shift from neuronal to glial cell involvement in early 4-repeat 221 222 tau pathology.

223 Of note, a small overlap may exist between our samples and some of those present in the GWAS 224 by Höglinger *et al*³, as 23 cases in the former study were recruited by Spanish centres. However, 225 this potential overlap comprises a very small fraction of the samples included in both datasets, 226 thus we do not expect it to substantially bias our results. In fact, PSP GWASs suffer from a 227 considerable "Russian doll" effect⁹, as new reports consist of expansions on previously available 228 cohorts, causing a large overlap between studies. Our study used exclusively Spanish and 229 Portuguese samples for validation of PSP susceptibility loci, and thus provides a highly 230 independent cohort for replication of the previously reported variants (Extended Data Table 3). Importantly, there is a striking lack of diversity in PSP genetic studies to date. Expanding future 231 232 studies to include non-European populations is crucial for a better understanding of the disease 233 etiology, enhancing genetic discovery and benefiting a broader range of the human population²⁴.

234 **References**

- 235 1. Boxer, A. L. et al. Advances in progressive supranuclear palsy: new diagnostic criteria,
- biomarkers, and therapeutic approaches. *The Lancet Neurology* **16**, 552–563 (2017).
- 237 2. Baker, M. et al. Association of an Extended Haplotype in the Tau Gene with Progressive
- 238 Supranuclear Palsy. *Human Molecular Genetics* **8**, 711–715 (1999).
- 239 3. PSP Genetics Study Group *et al.* Identification of common variants influencing risk of the
- tauopathy progressive supranuclear palsy. *Nat Genet* **43**, 699–705 (2011).
- 4. Sanchez-Contreras, M. Y. et al. Replication of progressive supranuclear palsy genome-wide
- association study identifies SLCO1A2 and DUSP10 as new susceptibility loci. *Mol*
- 243 *Neurodegeneration* **13**, 37 (2018).


- 5. Chen, J. A. *et al.* Joint genome-wide association study of progressive supranuclear palsy
- identifies novel susceptibility loci and genetic correlation to neurodegenerative diseases. *Mol*
- 246 *Neurodegeneration* **13**, 41 (2018).
- 6. Rojas, I. de et al. Common variants in Alzheimer's disease and risk stratification by
- 248 polygenic risk scores. *Nature Communications* **12**, 3417 (2021).
- 249 7. Taliun, D. *et al.* Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program.
- 250 *Nature* **590**, 290–299 (2021).
- 8. Höglinger, G. U. et al. Clinical diagnosis of progressive supranuclear palsy: The movement
- disorder society criteria: MDS Clinical Diagnostic Criteria for PSP. Mov Disord. 32, 853–
- **253** 864 (2017).
- 254 9. Escott-Price, V. & Hardy, J. Genome-wide association studies for Alzheimer's disease:
- bigger is not always better. *Brain Communications* **4**, fcac125 (2022).
- 256 10. Wang, H. et al. Whole-Genome Sequencing Analysis Reveals New Susceptibility Loci
- and Structural Variants Associated with Progressive Supranuclear Palsy. Preprint at

258 http://medrxiv.org/lookup/doi/10.1101/2023.12.28.23300612 (2023).

- 259 11. Farrell, K. et al. Genetic, Transcriptomic, Histological, and Biochemical Analysis of
- 260 Progressive Supranuclear Palsy Implicates Glial Activation and Novel Risk Genes. Preprint
- 261 at http://biorxiv.org/lookup/doi/10.1101/2023.11.09.565552 (2023).
- 262 12. Sherman, D. L. *et al.* Neurofascins Are Required to Establish Axonal Domains for
- 263 Saltatory Conduction. *Neuron* **48**, 737–742 (2005).
- 26413.Zhang, A. *et al.* Neurofascin 140 Is an Embryonic Neuronal Neurofascin Isoform That
- Promotes the Assembly of the Node of Ranvier. J. Neurosci. 35, 2246–2254 (2015).
- 266 14. Kira, J., Yamasaki, R. & Ogata, H. Anti-neurofascin autoantibody and demyelination.
- 267 *Neurochemistry International* **130**, 104360 (2019).
- Yang, C. *et al.* Genomic atlas of the proteome from brain, CSF and plasma prioritizes
 proteins implicated in neurological disorders. *Nat Neurosci* 24, 1302–1312 (2021).
- 270 16. Zoupi, L. et al. The function of contactin-2/TAG-1 in oligodendrocytes in health and
- 271 demyelinating pathology. *Glia* **66**, 576–591 (2018).

- 272 17. Sjöstedt, E. et al. An atlas of the protein-coding genes in the human, pig, and mouse
- 273 brain. *Science* **367**, eaay5947 (2020).
- 18. Gobert, R. P. et al. Convergent functional genomics of oligodendrocyte differentiation
- identifies multiple autoinhibitory signaling circuits. *Mol Cell Biol* **29**, 1538–1553 (2009).
- 276 19. Gu, G. J. et al. Role of Individual MARK Isoforms in Phosphorylation of Tau at Ser262
- 277 in Alzheimer's Disease. *Neuromol Med* **15**, 458–469 (2013).
- 278 20. Kahlson, M. A. & Colodner, K. J. Glial Tau Pathology in Tauopathies: Functional
- 279 Consequences. *J Exp Neurosci* **9s2**, JEN.S25515 (2015).
- 280 21. Allen, M. et al. Conserved brain myelination networks are altered in Alzheimer's and
- other neurodegenerative diseases. *Alzheimer's & amp; Dementia* 14, 352–366 (2018).
- 282 22. Briel, N., Pratsch, K., Roeber, S., Arzberger, T. & Herms, J. Contribution of the
- astrocytic tau pathology to synapse loss in progressive supranuclear palsy and corticobasal
- degeneration. *Brain Pathology* **31**, e12914 (2021).
- 285 23. Ling, H. et al. Astrogliopathy predominates the earliest stage of corticobasal
- degeneration pathology. *Brain* **139**, 3237–3252 (2016).
- 287 24. Graham, S. E. et al. The power of genetic diversity in genome-wide association studies
- 288 of lipids. *Nature* **600**, 675–679 (2021).

289 Figures



290

Fig. 1. PSP GWAS in the Spanish and Portuguese population and evaluation of the clinical 291 292 subgroups. a. Manhattan plot displaying PC-adjusted PSP genome-wide associations of common variants. b-c. QQ-plots displaying expected vs. observed p-values in our PSP GWAS including 293 294 and excluding chr17, respectively. **d.** Forest plot displaying effects of rs8070723, a variant tagging 295 the MAPT H1 haplotype in our histopathological and clinical Stage I samples. e. Effect sizes and 296 significance of the risk allele of known reported PSP risk variants, as reported by Sanchez-Contreras et al ⁴ **f.** Distribution of MAPT H1/H2 haplotypes in the different groups. OR, odds 297 298 ratio; PSP-RS, Richardson-Syndrome; nR-PSP, non-Richardson PSP.






Fig. 2. NFASC/CNTN2 is a novel locus for progressive supranuclear palsy. a. Forest plot
displaying effect sizes and meta-analysis of the rs12744678 C allele among the different cohorts.
b. Locus plot of the *NFASC/CNTN2* in cohorts where genome-wide association results were
available (PSP/DEGESCO and ADC). c. Gene ontology enrichment ratio calculated using
WebGestalt including PSP replicated loci (*MAPT*, *MOBP*, *EIF2AK3*, *STX6*, *DUSP10*, *SLCO1A2*)
and the novel *NFASC* locus.

306 **Online methods**

307 PSP/DEGESCO cohort

308 Stage I samples consisted of 176 histopathologically confirmed PSP samples recruited between 309 2002 and 2021 from Spanish and Portuguese brain biobanks, and 312 samples fulfilling a clinical diagnosis of probable PSP provided by research groups linked to DEGESCO (Supplementary 310 311 Table 1). Neuropathological diagnosis of PSP was assessed based on the distribution of neurofibrillary tangles in the brain, according to National Institute of Neurological Disorders and 312 Stroke (NINDS) criteria²⁵, while clinical diagnosis was based on the Movement Disorder Society 313 314 criteria⁸. Briefly, neurologists evaluated four functional domains: ocular motor dysfunction, 315 postural instability, akinesia and cognitive dysfunction. Considering these four domains a 316 probable PSP diagnosis can be assigned to not only patients with PSP-RS, but also to those 317 individuals with atypical clinical presentations, such as PSP with progressive gait freezing, with 318 predominant parkinsonism or with predominant frontal presentation. Controls in this study were 319 obtained from the GR@ACE/DEGESCO cohort (Supplementary Information)⁶. Finally, we 320 recruited an additional batch of PSP samples for further validation of our results (PSP/DEGESCO 321 Stage II), which included 39 histopathological and 154 clinical samples (Supplementary Table 1). 322 Written informed consent was obtained from all participants in this study. This study has been approved by the competent research ethical committee (MED-FACE-2020-01, Universidad 323 324 Internacional de Catalunya, Sant Cugat del Vallés, Spain).

325 Amsterdam Dementia Cohort

326 Patient records of 397 patients diagnosed with PSP and/or corticobasal degeneration within the 327 Amsterdam Dementia Cohort (ADC) between 2000 and 2023 were retrieved²⁶. A clinician 328 retrospectively evaluated each patient file, according the Movement Disorder Society criteria⁸, 329 for ocular motor dysfunction, postural instability, akinesia and cognitive dysfunction. For this 330 study, a total of 59 patients had genotyping available, were unrelated and of European ancestry, 331 and met criteria for PSP-RS. Controls were patients without cognitive complaints from the same 332 cohort (N=1105) and cognitively normal individuals from various other studies: one twin from each pair of twins from the EPAD study²⁷ (N=97), partners of children of participants from the 333 100-plus Study²⁸ (N=83) and controls included in the context of the Parelsnoer Institute²⁹ 334 (N=228). The local Medical Ethics Committees have approved the protocols for the ADC and the 335 other studies and all participants of the ADC provided written informed consent. 336

337 PSP/DEGESCO: DNA genotyping, QC & imputation

338DNA from PSP cases was genotyped by the Spanish National Center for Genotyping (CEGEN)

using the Axiom 815K Spanish Biobank Array (Thermo Fisher). We performed genotype calling

340 using Affymetrix power tools (APT) software v1.15.0, and curated calls following the Axiom 341 data analysis workflow. To improve calling accuracy we combined our cases with 5000 controls genotyped in the same center and using the same platform from the GR@ACE/DEGESCO 342 cohort^{6,30}. Called variants passing quality control (OC) criteria defined by the manufacturer 343 344 (Affymetrix) were kept for downstream analysis (N=737,174). After genotype calling, we 345 removed samples with low genotype call rates (<97%), high heterozygosity (+3SD over mean heterozygosity), discordant genetic-reported sex, and non-European ancestry, based on the 1000G 346 347 European population cluster. After sample QC, we removed variants with high missingness 348 (>5%), low frequency (MAF<0.01), differential missingness between cases and controls (p<10⁻⁵) 349 or failing the Hardy Weinberg equilibrium test $(p < 10^{-6})$ in the control population. Samples with genotype call rates below 0.97 after variant QC were also removed. Additionally, we excluded 350 duplicated and related individuals within our study by applying a GENESIS³¹ kinship filter of 351 0.046875. For PSP/DEGESCO Stage II samples, we merged the controls and cases passing OC 352 353 from Stage I during the genotype calling stage and followed the same procedure described above. 354 Additionally, at the IBD filtering step we removed Stage II cases overlapping or related to cases 355 from Stage I. A complete overview of the QC process is detailed at the Supplementary 356 Information section.

357 Amsterdam Dementia Cohort: genotyping, QC and imputation

358 We genotyped individuals using the Illumina Global Screening Array and applied established quality control methods³². We used high-quality genotypes in all individuals (individual call rate 359 360 >99%, variant call rate >99%), individuals with sex mismatches were excluded and departure 361 from Hardy-Weinberg equilibrium was considered significant at p < 1x10-6. Genotypes were then 362 lifted over to GRCh38 and prepared for imputation using provided scripts (HRC-1000G-check-363 bim.pl) specifying TOPMed as reference panel. This script compares variant ID, strand, and allele 364 frequencies to the TOPMed reference panel (version r2, N=194,512 haplotypes from N=97,256 365 individuals)⁷. Finally, all variants were submitted to the Michigan Imputation server (https://imputation.biodatacatalyst.nhlbi.nih.gov/). The server uses EAGLE (v2.4) to phase data 366 367 and Minimac4 to perform genotype imputation to the reference panel. After quality control and 368 genotype imputation of the genetic data, we kept only individuals of European ancestry (based on 369 1000Genomes clustering)³³, and excluded individuals with a family relation (identity-by-descent 370 ≥ 0.2)³⁴, leaving 59 clinically diagnosed PSP-RS cases and 1513 controls for analysis.

371 Statistical analysis

For GWAS analysis, we included approximately four sex-matched controls per PSP case available (Extended Data Table 2), as the increase in statistical power above this control-to-case ratio is generally negligible³⁵. We removed rare SNPs (MAF<0.01) or those with low imputation

375 quality (R2<0.3), leaving us with ~9M variants for association testing. To test the association of 376 SNP allele dosages with PSP risk we fitted logistic regression models using PLINK v2.00a3.7LM software. We adjusted the models by the first four PCs to account for population microstructure. 377 As we used population-based controls in our analysis, we did not adjust the models by age to 378 379 avoid jeopardizing small effects, since the large age differences between cases and controls would lead to adjustment for 'caseness', biasing the analysis towards the null³⁶. In addition, to ensure 380 that the association of tested variants was not age-driven, we ran PC-adjusted linear regressions 381 382 for age in the full subset (N=1,450) of Stage I controls (Supplementary Table 2). Additionally, to 383 check for H1/H2 independent associations around the MAPT gene, we ran models adjusted by the 384 rs1122380 genotype, which is in full linkage disequilibrium (LD) with rs1800547 (CEU: R2=1.00; D'=1.00), the SNP previously used to report MAPT H1/H2 haplotype effects in our 385 population³⁷. We performed fixed effect inverse variance-weighted meta-analysis of the discovery 386 and replication sets using the METAL software³⁸. Locus association plots were made using 387 388 LocusZoom (http://locuszoom.org/). All additional analyses, processing and visual representation 389 of the data were performed using R software v4.1.1. We strand corrected and flipped effect alleles 390 to align our results with the previous ones when needed and used the meta R package³⁹ to run 391 fixed effect inverse variance-weighed meta-analysis on specific SNPs.

392 In-silico functional analysis

Enrichment analysis was performed using WebGestalt⁴⁰ (https://www.webgestalt.org/).
Expression of target genes was assessed using GTEx Portal and Human Protein Atlas for RNA
and protein levels, respectively. The Online Neurodegenerative Trait Integrative Multi-Omics
Explorer (ONTIME) web resource was accessed to check association of variants with quantitative
endophenotypes¹⁵. Finally, gene co-expression networks were generated using GeneFriends
(https://www.genefriends.org/)⁴¹. Details on these methodologies are provided in the
Supplementary Information.

400 Data availability

The data that support the findings of this study are not openly available due to reasons of sensitivity and are available from the corresponding author upon reasonable request. Summary statistics detailing association results will be made publicly available upon acceptance of the manuscript.

405 **Code availability**

406 Custom code was used to calculate polygenic risk scores and is publicly available 407 (https://github.com/Pablo-GarGon/PRS_Generator). Other analyses were performed using

408 publicly available software, tools and algorithms, as detailed in the Methods and Supplementary

409 Information sections.

410 **References**

- 411 25. Hauw, J.-J. et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-
- 412 Olszewski syndrome (progressive supranuclear palsy). *Neurology* 44, 2015–2015 (1994).
- 413 26. Van Der Flier, W. M. & Scheltens, P. Amsterdam Dementia Cohort: Performing
- 414 Research to Optimize Care. *JAD* **62**, 1091–1111 (2018).
- 415 27. Konijnenberg, E. et al. The EMIF-AD PreclinAD study: study design and baseline
- 416 cohort overview. *Alz Res Therapy* **10**, 75 (2018).
- 417 28. Holstege, H. et al. The 100-plus Study of cognitively healthy centenarians: rationale,
- design and cohort description. *Eur J Epidemiol* **33**, 1229–1249 (2018).
- 419 29. Jansen, I. E. et al. Genome-wide meta-analysis for Alzheimer's disease cerebrospinal
- 420 fluid biomarkers. *Acta Neuropathol* **144**, 821–842 (2022).
- 421 30. Moreno-Grau, S. et al. Genome-wide association analysis of dementia and its clinical
- 422 endophenotypes reveal novel loci associated with Alzheimer's disease and three causality
- 423 networks: The GR@ACE project. *Alzheimer's & Dementia* **15**, 1333–1347 (2019).
- 424 31. Gogarten, S. M. et al. Genetic association testing using the GENESIS R/Bioconductor
- 425 package. *Bioinformatics* **35**, 5346–5348 (2019).
- 426 32. Das, S. *et al.* Next-generation genotype imputation service and methods. *Nat Genet* 48,
 427 1284–1287 (2016).
- 42833.The 1000 Genomes Project Consortium *et al.* A global reference for human genetic
- 429 variation. *Nature* **526**, 68–74 (2015).
- 430 34. Anderson, C. A. *et al.* Data quality control in genetic case-control association studies.
- 431 *Nature Protocols* **5**, 1564–1573 (2011).
- 432 35. Taylor, J. M. Choosing the number of controls in a matched case-control study, some
- 433 sample size, power and efficiency considerations. *Stat Med* **5**, 29–36 (1986).
- 434 36. Baker, E. *et al.* What does heritability of Alzheimer's disease represent? *PLoS ONE* 18,
 435 e0281440 (2023).

- 436 37. Sánchez-Juan, P. et al. The MAPT H1 Haplotype Is a Risk Factor for Alzheimer's
- 437 Disease in APOE ε4 Non-carriers. *Front. Aging Neurosci.* **11**, 327 (2019).
- 438 38. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of
- 439 genomewide association scans. *Bioinformatics* **26**, 2190–2191 (2010).
- 440 39. Balduzzi, S., Rücker, G. & Schwarzer, G. How to perform a meta-analysis with R: a
- 441 practical tutorial. *Evid Based Mental Health* **22**, 153–160 (2019).
- 442 40. Wang, J., Vasaikar, S., Shi, Z., Greer, M. & Zhang, B. WebGestalt 2017: a more
- 443 comprehensive, powerful, flexible and interactive gene set enrichment analysis toolkit.
- 444 *Nucleic Acids Research* **45**, W130–W137 (2017).
- 445 41. Raina, P. et al. GeneFriends: gene co-expression databases and tools for humans and
- 446 model organisms. *Nucleic Acids Research* **51**, D145–D158 (2023).

447 Acknowledgements

The present work has been performed as part of the Doctoral thesis of Pablo García-González at 448 449 the University of Barcelona (Barcelona, Spain). We would like to thank patients and controls who participated in this project. Some control samples and data from patients included in this study 450 451 were provided in part by the National DNA Bank Carlos III (www.bancoadn.org, University of 452 Salamanca, Spain) and Hospital Universitario Virgen de Valme (Sevilla, Spain); they were processed following standard operating procedures with the appropriate approval of the Ethical 453 454 and Scientific Committee. We are grateful to the Biomedic Diagnostic Center (CBD) of the 455 Hospital Clinic de Barcelona for access to, and assistance with, FLUOSTAR Omega equipment 456 and RT-QuIC experiments (Drs. Raquel Ruiz and Laura Naranco). Hospital Clinic de Barcelona 457 receives support from the CERCA programme from Generalitat de Catalunya (Catalan 458 government). Several authors of this manuscript are members of the European Reference Network 459 for Rare Neurological Diseases - Project ID No 739510, as well as CIBERNED (CB06/05/0018-460 ISCIII). We acknowledge the Biobank of the University of Navarra for its collaboration. We thank all study participants and all personnel involved in data collection for the contributing 461 studies. Research of Alzheimer Center Amsterdam is part of the neurodegeneration research 462 463 program of Amsterdam Neuroscience. Alzheimer Center Amsterdam is supported by Stichting 464 Alzheimer Nederland and Stichting Steun Alzheimercentrum Amsterdam. The chair of Wiesje 465 van der Flier is supported by the Pasman stichting. The clinical database structure was developed 466 with funding from Stichting Dioraphte. The work in this manuscript was carried out on the 467 Snellius supercomputer, which is embedded in the Dutch national e-infrastructure with the 468 support of SURF Cooperative. Computing hours were granted in 2016, 2017, 2018 and 2019 to 469 H. Holstege by the Dutch Research Council (project name: '100plus'; project numbers 15318 and 470 17232). Samples and data from patients included in this study were provided by the Vall d'Hebron 471 University Hospital Biobank (PT20/00107), integrated in the Spanish National Biobanks Network, and they were processed following standard operating procedures with the appropriate 472 approval of the Ethical and Scientific Committees. We are indebted to the Biobank-Hospital 473 474 Clinic-FRCB-IDIBAPS for samples and data procurement. This work was funded by CIBERNED 475 (Centro Investigación Biomédica en Red Enfermedades Neurodegenerativas) 10th internal call 476 for cooperative projects (Register number: 2019/09). Agustín Ruiz, Pascual Sanchez-Juan, 477 Alberto Rábano, and Maria J. Bullido received funding from this convocatory. Pablo García-478 González received support by CIBERNED employment plan CNV-304-PRF-866. CIBERNED is 479 integrated into ISCIII (Instituto de Salud Carlos III). Mercé Boada, Marta Marquié and Agustín Ruiz are also supported by national grants PI13/02434, PI16/01861, PI17/01474, PI19/01240. 480 PI19/01301, PI19/00335 and PI22/011403, and CIBERNED grant 2019/08. The Genome 481 482 Research @ Fundació ACE project (GR@ACE) is supported by Grifols SA, Fundación bancaria "La Caixa", Fundació ACE, and CIBERNED. Acción Estratégica en Salud is integrated into the 483 Spanish National R + D + I Plan and funded by ISCIII—Subdirección General de Evaluación and 484 485 the Fondo Europeo de Desarrollo Regional (FEDER—"Una manera de hacer Europa"). Agustín 486 Ruiz is supported by ISCIII national grant PMP22/00022, funded by the European Union 487 (NextGenerationEU). The genotyping service to generate GR@ACE and PSP/DEGESCO GWAS data was carried out at CEGEN-PRB3-ISCIII; it is supported by grant PT17/0019, of the PE I+D+i 488 2013-2016, funded by ISCIII and ERDF". Itziar de Rojas received support by a national grant 489 490 from ISCIII FI20/00215. Amanda Cano acknowledges the support of the Spanish Ministry of 491 Science, Innovation and Universities under the grant Juan de la Cierva (FJC2018-036012-I), the 492 support of ISCIII under the grant Sara Borrell (CD22/00125), Spanish Ministry of Science and 493 Innovation, Proyectos de Generación de Conocimiento grant PID2021-122473OA-I00, and

494 Fundación ADEY under the program "Proyectos de Investigación en Salud 2023". Fondo de Investigacion en Salud (Instituto Carlos III) (PI17/00096) in the frame of the European Regional 495 Development Fund (ERDF) and to Fundacio la Marato de TV3 (PI043296 and 202009-10). This 496 work was supported by the Spanish Ministry of Science and Innovation (RTC2019-007150-1), 497 498 the Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union (PI14/01823, 499 PI16/01575, PI18/01898, PI19/01576, PI21/01875), the Consejería de Economía, Innovación, 500 Ciencia y Empleo de la Junta de Andalucía (CVI-02526, CTS-7685, PY20_00896), and the 501 Consejería de Salud y Bienestar Social de la Junta de Andalucía (PI-0471-2013, PE-0210-2018, 502 PI-0459-2018, PE-0186-2019). Pilar Gómez-Garre was supported by the "Nicolás Monardes" 503 program (C-0048-2017) from Andalusian Regional Ministry of Health. Laura Muñoz-Delgado 504 was supported by the "Río Hortega" program [CM21/00051] from the Instituto de Salud Carlos 505 III (ISCIII-FEDER). The funders had no role in study design, data collection and analysis, 506 decision to publish, or preparation of the manuscript. Sven J. van der Lee was funded for this 507 study by NWO (#733050512, PROMO-GENODE: a PROspective study of MOnoGEnic causes 508 Of Dementia) a substantial donation by Edwin Bouw Fonds and Dioraphte. SvdL further received 509 funding for the GeneMINDS consortium, which is powered by Health~Holland, Top Sector Life 510 Sciences & Health. Sven J. van der Lee is a recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and Health~Holland, Topsector 511 512 Life Sciences & Health (PPP-allowance; #LSHM20106). More than 30 partners participate in 513 ABOARD. ABOARD also receives funding from Edwin Bouw Fonds and Gieskes-Strijbisfonds. 514 ABOARD also receives funding from de Hersenstichting, Edwin Bouw Fonds and Gieskes-515 Strijbisfonds. Array genotyping was performed in the context of EADB (European Alzheimer 516 DNA biobank) funded by the JPco-fuND FP-829-029 (ZonMW projectnumber 733051061). This 517 work has been supported by the Queen Sofia Foundation. Pascual Sánchez-Juan is supported by 518 grants from ISCIII (PMP22/00022 and PI20/01011) and TED2021-131676B-100. Luis Miguel 519 Real received support from "The absence of seroconversion after exposition to hepatitis C virus is not related to KIR-HLA genotype combinations" (GEHEP-012 study). Consejería de Salud de 520 521 la Junta de Andalucía (grant number PI-0001/2017) and CIBERINFEC -Consorcio Centro de 522 Investigación Biomédica en Red de Enfermedades Infecciosas- Instituto de Salud Carlos III, 523 Ministerio de Ciencia e Innovación y Unión Europea (Spain) (NextGeneration EU) (grant number 524 CB21/13/00118). Jose Luis Royo received support from Project 23.04.2021 from Santángela 525 Foundation (Sevilla, Spain).

526 **Contributions**

- 527 P.Gar-Gon. wrote the manuscript. Y.C., V.F., M.Bu., A.Ra., P.S-J., and A.Ru. jointly supervised
- 528 the work. H.R.L., M.Bu., A.Ra., P.S-J., and A.Ru. designed and conceptualized the study. P.Gar-
- 529 Gon., S.vdL., and M.H performed bioinformatics and statistical analyses. P.Gar-Gon., M.F.,
- 530 S.vdL., I.dR., L.S., R.P., C.O., Y.P., I.Q., A.C., and H.H. were involved in data generation.
- 531 H.R.L., Y.C., M.F., S.vdL., L.S., C.P., A.Cam., E.M., M.J.M., F.V., I. I-G., J.P., I. D-I., J, K, J.F.,
- 532 A.L.I., S.CM.dB., Y.P., R.D-B., L.M-D., D.B-R., P.Gom-Gar., I.A., G.Ar., J.H.V., M.Me., J.P-T-
- 533 , P.J.V., A.d.B., J.M.P., A.M.M., L.T., L.M.R., JL. R., M.E.E., C.G., D.C.T., M.B.E., B.S.M.,
- 534 S.T.B., D.V.R., I.H., A.S-S., B.C-F., S.R.L., R.B.M., A.La., R.T., G.Am., E.M.S., M.F-M., C.L-
- 535 M., V.A., L.M.P., H.H., P.M., O.B., and M.Bo. were involved in sample contribution. All authors
- 536 critically revised the manuscript for important intellectual content and approved this final version.

537 **Competing interests**

- 538 Vigil Neuroscience and Prevail therapeutics are in a public-private partnerschip research program
- of Sven J. van der Lee. All funding is paid to his institution.

Extended Data

N 488 400 392 389	Fail 88 8 3	Fail (%) 18.03% 2.00%	N NA 5000	Fail NA 26	Fail (%) NA
400 392	8 3	2.00%			
392	3	2.00%	5000	26	
					0.52%
389	10	0.77%	4974	4	0.08%
	10	2.57%	4970	0	0.00%
379	6	1.58%	4970	15	0.30%
373	20	5.36%	4955	300	6.05%
353			4655		
	PSP			Controls	
Ν	Fail	Fail (%)	Ν	Fail	Fail (%)
193	0	0.00%	NA	NA	NA
193	12		5000	12	0.24%
181	0	0.00%	4988	0	0.00%
181	1	0.55%	4988	0	0.00%
180	0	0.00%	4988	10	0.20%
180	11	6.11%	4978	302	6.07%
169			4676		
-	373 353 N 193 193 181 181 180 180	373 20 353 PSP N Fail 193 0 193 12 181 0 181 1 180 0 180 11	373 20 1.58% 353 5.36% 353 PSP N Fail Fail (%) 193 0 0.00% 193 12 6.22% 181 0 0.00% 181 1 0.55% 180 0 0.00% 180 11 6.11%	373 20 1.58% 353 4955 353 4655 PSP 4655 N Fail 193 0 193 12 6.22% 5000 181 0 181 1 0.00% 4988 181 1 180 0 180 11 6.11% 4978	$\begin{array}{c c c c c c c c c c c c c c c c c c c $

Extended Data Table 1. Summary of samples remaining after QC steps in the PSP/DEGESCO cohort.

Extended Data Table 2. Demographic features of samples included in the Spanish and Portuguese PSP GWAS used for replication of previous known PSP *loci*.

		CA		СО			
-	Ν	%Males	Age* (SD)	Ν	%Males	Age* (SD)	
PSP/DEGESCO Stage I (histopathological)	156	56.4	76.5 (9.5)	650	56.5	67.8 (10.1)	
PSP/DEGESCO Stage I (PSP-RS)	112	48.2	67.2 (7.8)	800	46.8	68.6 (10.3)	
PSP/DEGESCO Stage II (hist. + PSP-RS)	119	54.6	69.2 (8.2)	500	54.6	68.1 (10.5)	
TOTAL	465			1950			
N, sample size; SD, standard deviation.							

*Controls: Mean age at last visit; histopathological PSP: Mean age at death; clinical PSP: Mean age at motor symptoms onset.

Extended Data Table 3. Summary statistics of the replication in Spanish and Portuguese population of PSP GWS susceptibility *loci* reported to date. The direction column shows the effect directions in the PSP/DEGESCO Stage I histopathological, PSP/DEGESCO Stage I PSP-RS, and PSP/DEGESCO Stage II, respectively. Genomic coordinates correspond to the GRCh38 assembly. EA, effect allele; OA, other allele; OR, odds ratio; SE, standard error; P, p-value; CI, confidence interval.

							PSP/DEGESCO					
rs	CHR	POS	EA	OA	Gene	OR*** (reported)	OR	SE	Р	CI 2.5%	CI 97.5%	Direction
rs8070723	chr17	46003698	А	G	MAPT	5.511	4.02	0.13	9.89.10-27	3.12	5.19	+++
rs242557*	chr17	45942346	G	А	MAPT	0.51^{1}	0.72	0.09	2.49.10-04	0.61	0.86	
rs1768208	chr3	39481512	G	А	MOBP	0.691	0.76	0.08	$1.02 \cdot 10^{-03}$	0.64	0.89	
rs7571971	chr2	88595833	С	Т	EIF2AK3	0.77^{1}	0.80	0.09	9.06·10 ⁻⁰³	0.68	0.95	
rs1411478	chr1	180993146	G	А	STX6	0.791	0.84	0.08	2.63.10-02	0.71	0.98	
rs11568563	chr12	21304500	А	С	SLCO1A2	0.67^{1}	0.54	0.13	$1.17 \cdot 10^{-06}$	0.42	0.69	
rs6687758	chr1	221991606	А	G	DUSP10	0.80^{1}	0.80	0.10	2.03.10-02	0.66	0.97	
rs6458446	chr6	45532733	А	G	RUNX2	0.77 ²	0.90	0.10	0.27	0.75	1.09	-+-
rs429358	chr19	44908684	С	Т	APOE (E4)	0.55 ³	0.72	0.15	2.46.10-02	0.53	0.96	
rs7412	chr19	44908822	Т	С	<i>APOE</i> (ε2)	2.39 ³	1.08	0.16	0.64	0.78	1.49	-++

rs369580**	chr6	32052461	А	G	TNXB/C4A	1.43^{4}	1.25	0.19	0.24	0.86	1.82	++NA
------------	------	----------	---	---	----------	------------	------	------	------	------	------	------

* Adjusted by MAPT H1 dose (rs1122380)
** This variant was not correctly imputed in PSP/DEGESCO Stage II.
***Study: 1 - Sanchez-Contreras *et al.* 2018¹. 2 - Chen *et al.* 2018², 3- Wang *et al.* 2023 (medRxiv)³; 4- Farrell *et al.* 2023 (BioRxiv)⁴

Extended Data Table 4. Main features of the cohorts available for meta-analysis.

		PSP			Control	
- Variants available	N	Males (%)	Age (SD)	Ν	Males (%)	Age (SD)
4,099	2120	54.0	~66.5 (NA)	6847	NA	NA
37	533	55.0	75.0 (7.6)	1172	52.5	77.0 (8.9)
8,990,045	156	56.4	76.5 (9.5)	650	56.5	67.8 (10.1)
9,008,824	112	48.2	67.2 (7.8)	800	46.8	68.6 (10.3)
8,433,148	119	54.6	69.2 (8.2)	500	54.6	68.1 (10.5)
8,794,028	59	54.2	67.7 (5.5)	1513	58.5	62.3 (10.5)
36	3099			11482		
	available 4,099 37 8,990,045 9,008,824 8,433,148 8,794,028	available N 4,099 2120 37 533 8,990,045 156 9,008,824 112 8,433,148 119 8,794,028 59	Variants availableNMales (%)4,099212054.03753355.03753355.08,990,04515656.49,008,82411248.28,433,14811954.68,794,0285954.2	Variants availableNMales (%)Age (SD)4,099212054.0~66.5 (NA)3753355.075.0 (7.6)8,990,04515656.476.5 (9.5)9,008,82411248.267.2 (7.8)8,433,14811954.669.2 (8.2)8,794,0285954.267.7 (5.5)	Variants availableNMales (%)Age (SD)N4,099212054.0~66.5 (NA)68473753355.075.0 (7.6)11728,990,04515656.476.5 (9.5)6509,008,82411248.267.2 (7.8)8008,433,14811954.669.2 (8.2)5008,794,0285954.267.7 (5.5)1513	Variants availableNMales (%)Age (SD)NMales (%)4,099212054.0~66.5 (NA)6847NA3753355.075.0 (7.6)117252.58,990,04515656.476.5 (9.5)65056.59,008,82411248.267.2 (7.8)80046.88,433,14811954.669.2 (8.2)50054.68,794,0285954.267.7 (5.5)151358.5

N, sample size; SD, standard deviation.


*Controls: Mean age at last visit; histopathological PSP: Mean age at death; clinical PSP: Mean age at motor symptoms onset.

Extended Data Table 5. Summary statistics of the meta-analysis of the 36 SNPs available SNPs including data from the Höglinger *et al.*⁵ and Sanchez-Contreras et al.¹ studies, PSP/DEGESCO and ADC. Genomic coordinates correspond to the GRCh38 assembly. EA, effect allele; OA, other allele; OR, odds ratio; P, p-value; EAF, effect allele frequency; SE, standard error; CI, confidence interval; I2, heterogeneity estimate.


SUPPLIED SEPARATELY IN EXCEL FORMAT

Extended Data Table 6. Top enriched genesets using the WebGestalt Over Representation Analysis including the 6 PSP loci replicated in the PSP/DEGESCO cohort (*MAPT, MOBP, EIF2AK3, STX6, DUSP10* and *SLCO1A2*) and the novel *NFASC* locus. Size depicts the number of genes in the geneset. Overlap depicts the number of genes in our input list present in the geneset. Expect depicts the number of genes expected to overlap with each geneset at random given the number of imputed genes.


geneSet	Description	Size	Overlap	Expect	Enrichment	Р	FDR	database
					Ratio			
GO:0097386	glial cell projection	23	2	0.01047563	190.9	4.48E-05	0.06	Cellular Component
GO:0031072	heat shock protein binding	113	2	0.05146724	38.9	1.10E-03	0.52	Molecular Function
GO:0007272	ensheathment of neurons	118	2	0.05374455	37.2	1.20E-03	0.52	Biological Process
GO:0043209	myelin sheath	155	2	0.07059666	28.3	2.05E-03	0.67	Cellular Component
GO:0019902	phosphatase binding	177	2	0.08061683	24.8	2.67E-03	0.68	Molecular Function
GO:0009266	response to temperature stimulus	192	2	0.08744876	22.9	3.13E-03	0.68	Biological Process
GO:0051348	negative regulation of transferase	258	2	0.11750927	17.0	5.58E-03	0.69	Dielegiaal Drosses
60:0031348	activity		2					Biological Process
GO:0042063	gliogenesis	261	2	0.11887566	16.8	5.70E-03	0.69	Biological Process
CO.0051061	negative regulation of nervous	294	2	0 10200501	14.9	7.19E-03	0.69	Dielegiaal Drosses
GO:0051961	system development	294	2	0.13390591	14.9	7.19E-05	0.09	Biological Process
GO:0048638	regulation of developmental growth	312	2	0.14210424	14.1	8.06E-03	0.69	Biological Process
P, p-value; FD	R, false discovery rate adjusted p-value.							




Extended Data Fig. 1.a. Overview of the quality control process for PSP cases and controls. **b.** Scatterplot of the first two principal components calculated using the 1000 Genomes dataset⁶, showing the different 1000G populations and the samples in PSP/DEGESCO Stage I. We removed samples in PSP/DEGESCO that were outliers (3 standard deviations away from the mean) with respect to the 1000G European cluster. **c.** Scatterplot representing sample call rates and heterozygosity rates in PSP/DEGESCO Stage I. Contaminated samples are expected to display an increase in both the proportion of uncalled genotypes and heterozygosity rate. **d.** City of origin of duplicated individuals found across PSP/DEGESCO Stage I clinics and brain biobanks.



Extended Data Fig. 2. Schematic depiction of cohorts used and steps taken in our study.




Extended Data Fig. 3. a. Association of rs4951151, the top variant detected in the *NFASC/CNTN2* locus with quantitative endophenotypes available on ONTIME https://ontime.wustl.edu/)⁷. Significant signals were observed for contactin-2 protein levels in CSF and plasma. **b.** Top correlated genes in the Human Protein Atlas single cell expression cluster⁸ for CNTN2, referred to as 'cluster 51'. **c.** Gene ontology treemap of the expression cluster 51, showing the main molecular functions, cellular components and biological processes enriched among these genes. **d.** Gene ontology enrichment for genes in cluster 51 performed using WebGestalt⁹.



Extended data Fig. 4. RNA expression levels by cell type for *MOBP*, *SLCO1A2*, *DUSP10*, *NFASC* and *CNTN2*, respectively, based on data from the Human Protein Atlas⁸.

1



- 2
- 3

4 **Extended Data Fig. 5.** Gene coexpression network generated using GeneFriends¹⁰ from our input

- 5 gene list: *MAPT, MOBP, EIF2AK3, STX6, DUSP10, SLCO1A2, NFASC* and *CNTN2*. Edges were
- 6 labelled with the Pearson correlation coefficient existent between transcripts belonging to the7 network.
- 8

9 **References**

- 10 1. Sanchez-Contreras, M. Y. et al. Replication of progressive supranuclear palsy genome-wide
- 11 association study identifies SLCO1A2 and DUSP10 as new susceptibility loci. *Mol*
- 12 *Neurodegeneration* **13**, 37 (2018).
- 13 2. Chen, J. A. et al. Joint genome-wide association study of progressive supranuclear palsy
- 14 identifies novel susceptibility loci and genetic correlation to neurodegenerative diseases. *Mol*
- 15 *Neurodegeneration* **13**, 41 (2018).
- 16 3. Wang, H. et al. Whole-Genome Sequencing Analysis Reveals New Susceptibility Loci and
- 17 Structural Variants Associated with Progressive Supranuclear Palsy. Preprint at
- 18 http://medrxiv.org/lookup/doi/10.1101/2023.12.28.23300612 (2023).
- 19 4. Farrell, K. et al. Genetic, Transcriptomic, Histological, and Biochemical Analysis of
- 20 Progressive Supranuclear Palsy Implicates Glial Activation and Novel Risk Genes. Preprint
- 21 at http://biorxiv.org/lookup/doi/10.1101/2023.11.09.565552 (2023).
- 22 5. PSP Genetics Study Group *et al.* Identification of common variants influencing risk of the
- tauopathy progressive supranuclear palsy. *Nat Genet* **43**, 699–705 (2011).
- 6. The 1000 Genomes Project Consortium *et al.* A global reference for human genetic variation.
- 25 *Nature* **526**, 68–74 (2015).
- 26 7. Yang, C. et al. Genomic atlas of the proteome from brain, CSF and plasma prioritizes
- 27 proteins implicated in neurological disorders. *Nat Neurosci* **24**, 1302–1312 (2021).
- 28 8. Karlsson, M. *et al.* A single–cell type transcriptomics map of human tissues. *Sci. Adv.* 7,
- eabh2169 (2021).
- 30 9. Wang, J., Vasaikar, S., Shi, Z., Greer, M. & Zhang, B. WebGestalt 2017: a more
- 31 comprehensive, powerful, flexible and interactive gene set enrichment analysis toolkit.
- 32 *Nucleic Acids Research* **45**, W130–W137 (2017).
- Raina, P. *et al.* GeneFriends: gene co-expression databases and tools for humans and
 model organisms. *Nucleic Acids Research* 51, D145–D158 (2023).
- 35

Supplementary Information: A Novel Susceptibility Locus in *NFASC* Highlights Oligodendrocytes and Myelination in Progressive Supranuclear Palsy Pathology

39 1. <u>Supplementary notes: DNA genotyping, QC & imputation in the PSP/DEGESCO cohort</u>

DNA from PSP cases was extracted from 25 mg of cerebellar cortex (histopathological PSP) or 40 peripheral blood (clinical PSP). After excluding samples with insufficient concentration (<5 41 ng/µL) or degraded DNA, samples were genotyped by the Spanish National Center for 42 Genotyping (CEGEN) using the Axiom 815K Spanish Biobank Array (Thermo Fisher). We 43 44 performed genotype calling and OC using Affymetrix power tools (APT) software v1.15.0 45 following the Axiom data analysis workflow. We kept samples with dishQC values >0.82, a parameter determined by measuring the resolution of AT and GC channels within monomorphic 46 47 SNPs, and genotype call rates >0.97. We also checked that the average call rate within plates was 48 >0.985 to detect potentially problematic batches. We jointly performed genotype calling for the 49 remaining PSP samples and 5,000 Spanish controls obtained from the GR@ACE/DEGESCO 50 cohort, which had been previously genotyped with the same platform, using the same array and in the same centre, thus minimizing potential batch effects^{1,2}. Called variants passing quality 51 52 control (QC) criteria defined by the manufacturer (Affymetrix) were kept for downstream analysis 53 (N=737,174).

After genotype calling, we removed samples with low genotype call rates (<97%) and high 54 55 heterozygosity (+3SD over mean heterozygosity). To identify mislabelled samples, we performed 56 a sex-check and removed those with discordant reported and genetic sex. We ran a principal 57 component (PC) analysis to identify and remove samples from non-European ancestries based on 58 the 1000 Genomes European population cluster (Extended Data Fig. 1). After sample QC, we removed variants with high missingness (>5%), low frequency (MAF<0.01), differential 59 missingness between cases and controls $(p<10^{-5})$ or failing the Hardy Weinberg equilibrium test 60 61 $(p<10^{-6})$ in the control population. Samples with genotype call rates below 0.97 after variant QC 62 were also removed from the dataset. Genotype imputation was performed for 379 PSP samples 63 and 4,955 controls in the TOPMed Imputation Server (Michigan, USA) using the TOPMed 64 reference panel based on 587,195 genotyped variants passing QC. Prior to GWAS analysis, we used the GENESIS R package³ to detect and remove potential cryptic relatedness within our 65 66 population. We first used a kinship filter of 0.45 to identify and remove sample pairs 67 corresponding to the same individual (N=11). After removing duplicates, we detected related pairs by applying a kinship filter of 0.046875, which represents the theoretical kinship value 68 69 between third- and fourth-degree relatedness. We first removed the samples present in multiple 70 related pairs, and for the remaining unique relative pairs we applied the following criteria: 1) if

71 one sample was a PSP and the other one was a control we removed the control; 2) if one sample 72 was a histopatologically confirmed PSP the other sample was a clinical PSP, we kept the 73 histopathological PSP; 3) if both samples belonged to the same clinical group (control, clinical or 74 histopathological PSP), we kept the sample with the highest genotype call rate. For 75 PSP/DEGESCO Stage II samples, we performed the genotype calling including the controls and 76 cases passing QC from Stage I, and followed the same procedure described above. Additionally, 77 at the IBD filtering step we removed Stage II cases overlapping or related to cases from Stage I. 78 An overview of the complete QC process is provided (Extended Data Fig. 1, Extended Data Table 79 1, Supplementary Table 1).

80 81

2. <u>Supplementary notes: DNA genotyping, QC & imputation in the Amsterdam Dementia</u> Cohort

We genotyped all individuals using the Illumina Global Screening Array and applied established 82 quality control methods⁴. We used high-quality genotypes in all individuals (individual call rate 83 >99%, variant call rate >99%), individuals with sex mismatches were excluded and departure 84 85 from Hardy-Weinberg equilibrium was considered significant at p < 1x10-6. Genotypes were then 86 lifted over to GRCh38 and prepared for imputation using provided scripts (HRC-1000G-check-87 bim.pl) specifying TOPMED as reference panel. This script compares variant ID, strand, and 88 allele frequencies to the TOPMED reference panel (version r2, N=194,512 haplotypes from 89 N=97,256 individuals)⁵. Finally, all variants were submitted to the Michigan Imputation server (https://imputation.biodatacatalyst.nhlbi.nih.gov/). The server uses EAGLE (v2.4) to phase data 90 91 and Minimac4 to perform genotype imputation to the reference panel. After quality control and 92 genotype imputation of the genetic data, we kept only individuals of European ancestry (based on 93 1000Genomes clustering)⁶, and excluded individuals with a family relation (identity-by-descent 94 ≥ 0.2)⁷, leaving 59 clinically diagnosed PSP-RS cases and 1513 controls for analysis.

95

96 3. <u>Supplementary notes: Detecting potential clinical heterogeneity using genetic</u> 97 <u>information.</u>

We leveraged the MAPT H1 haplotype, a well-known genetic risk factor for PSP⁸, to make 98 99 inferences on misdiagnose rates in the Stage I clinical PSP dataset and its subgroups. We 100 considered the confirmed pathological PSP cases as a reference of a pure PSP group, and the 101 controls as a reference for a non-PSP population. Theoretically, for a mix of PSP and non-PSP 102 samples, the expected value of the MAPT H1 allele frequency (AF) should range between its frequency in the pure/histopathological PSP (H1_{Freq}=0.9199), and the non-PSP (H1_{Freq}=0.7024) 103 104 populations in our study, and should be proportional to the ratio of PSP/non-PSP samples in the 105 mix. Thus, the MAPT H1 AF in the mixed sample would be equal to the MAPT H1 AF in the

histopathological PSP sample minus the difference in AF between the histopathological PSP and
control groups, (i.e. the total AF range between the pure PSP and non-PSP groups), multiplied by
the proportion of misdiagnosed samples in the mix:

$$Fg = Fh - M \cdot (Fh - Fc)$$

Fg: MAPT H1 AF in the mixed group; Fh: MAPT H1 AF in the histopathological PSP group (AF=0.9199);
 M: misdiagnose rate; Fc: MAPT H1 AF in the non PSP group (AF=0,7024); In the case of using logistic
 regression-derived effect sizes instead of frequencies, the log(OR) of these groups can be introduced instead

113 *of AF values.*

114 Rearranging the terms in this equation, we can estimate the percentage of misclassified samples115 in each group:

116
$$Misdiagnose (\%) = 100 \cdot \frac{Fh - Fg}{Fh - Fc}$$

117 (Fh - Fg), difference in MAPT H1 AF between the histopathological PSP and mixed group.

118 (Fh – Fc), difference in MAPT H1 AF between the histopathological PSP and the general 119 population.

120 The same logic can be applied using linear effect size estimates (log odds ratios) derived from 121 logistic regressions instead of AFs. As population microstructure might affect the MAPT H1 allele frequency in the Iberian population⁹, we also calculated the misclassification rates using the log 122 123 odds ratios obtained from fitting logistic regressions adjusted by the first four PCs in each 124 subgroup. For better comparability between all groups, we included the controls from the 125 discovery and validation setup (N=1,450) in all models. Additionally, because a proportion of the misclassified patients are expected to have Parkinson's Disease (PD)¹⁰ and the MAPT H1 locus 126 is known to also be a risk factor for PD, we used a OR=1.00 (neutral) and a OR=1.32 (Parkinson's 127 Disease MAPT H1)¹¹ to calculate the effect size-based misdiagnosis estimations. 128

129 4. <u>Supplementary notes: PRS calculation</u>

130 We calculated the PRS of AD, PD, amyotrophic lateral sclerosis (ALS), PSP and all stroke (AS) using reported genome-wide significant variants¹²⁻¹⁶. We constructed the PRSs selecting only 131 those variants with MAF>0.01 and imputation quality R2>0.3 in our dataset (Supplementary 132 133 Tables 3-7). A few considerations were taken in the AD PRS calculation: a) No APOE variants 134 were included, b) variants with MAF<0.01 were kept since these were previously validated in the original publication and they had very good imputation quality in our dataset ($R_{2}>0.9$), c) because 135 136 some controls of our study were included in the first stage of the AD GWAS, we used the 137 independent effects reported exclusively in the second stage. To calculate the different PRSs, we designed a custom software (https://github.com/Pablo-GarGon/PRS Generator) that added the 138

dosages of the risk alleles multiplied by their reported effect sizes (betas). Finally, we also
calculated the PRSs excluding the chromosome 17 to avoid pleiotropic effects caused by
including variants linked to the *MAPT locus*.

142 143

5. <u>Supplementary notes: A Decreased burden of known PSP genetic risk factors was</u> <u>detected in atypical PSP clinically diagnosed cases</u>

144 Because, to our very best knowledge, this the first case-control PSP GWAS including clinical 145 cases diagnosed using the recently proposed MDS criteria for probable PSP¹⁷, and our MAPT H1 146 association results suggested the existence of phenotypic heterogeneity in our clinical PSP cohort 147 (Fig. 1), we decided to estimate genetically-based misclassification rates in the available Stage I clinical PSP subjects (Supplementary Table 1). We classified these samples into four subgroups 148 149 based on two criteria: a) Samples with or without confirmed Richardson's Syndrome and b) 150 samples recruited by movement disorder units or memory clinics. The first classification allowed us to examine the specificity of the MDS criteria for assigning a probable PSP diagnosis to non-151 152 Richardson PSP (nR-PSP) patients, while the second one is useful to study potential ascertainment 153 bias caused by the recruitment in different neurology set-ups (movement disorders units and 154 memory clinics). As expected, the highest MAPT H1 frequency and effect size was found in the histopathological PSP group, and the misclassification estimates were considerably larger for nR-155 156 PSP than for PSP-RS samples (Fig. 1, Supplementary Table 1). Moreover, MAPT H1 frequencies 157 were significantly reduced in the nR-PSP patients compared to histopathological PSP (χ^2 =6.29; 158 DF=1; p=0.01), while no significant differences were observed for the PSP-RS patients in this 159 comparison ($\chi^2=0.16$; DF=1; p=0.69), supporting the presence of misclassified patients in the nR-160 PSP group. Interestingly, PSP-RS samples had similar misclassification rates despite recruitment 161 centre, while nR-PSP samples recruited in memory clinics displayed lower misdiagnose rates than 162 those recruited by movement disorder units, although these differences were not significant 163 $(\chi^2 = 1.38; DF = 1; p = 0.24).$

164 To further complement these results, we generated the AD, PD, ALS, PSP and AS PRSs using 165 known disease susceptibility variants and compared the PRS values between our PSP subgroups 166 and controls (Supplementary Fig. 1, Supplementary Table 10). The AD PRS was significantly increased in both nR-PSP subgroups: memory-clinic (OR[95%CI]=2.42[1.10-5.35]; p=0.03) and 167 168 movement disorder unit-recruited (OR/95%CI)=2.64[1.13–6.22]; p=0.03). Meanwhile, the PD 169 PRS was associated with disease status in both groups recruited by movement disorder units: PSP-RS (OR[95%CI]=1.90[1.22-2.96]; p=0.004) and nR-PSP (OR[95%CI]=1.72[1.00-2.93];170 171 p=0.05). Finally, the PSP PRS was associated with disease status in all subgroups except 172 movement disorder recruited nR-PSP (OR[95%CI]=1.20[0.96-1.52]; p=0.12), and no significant 173 associations were found between disease status and the ALS and AS PRSs. Because MAPT is a

pleiotropic risk factor for multiple neurodegenerative diseases, we repeated this analysis 174 175 excluding chromosome 17. After removing variants in the MAPT locus, an increase could still be 176 observed for the AD PRS in the nR-PSP subgroups and for the PD PRS in movement disorder unit-recruited subgroups, but the statistical significance was lost (Supplementary Fig. 1, 177 178 Supplementary Table 7). Interestingly, the association with the PSP PRS was lost in both nR-PSP 179 subgroups, and even showed a non-significant opposite effect direction in movement disorder 180 recruited nR-PSP patients (OR[95%CI]=0.69[0.32-1.48]; p=0.34). Furthermore, none of the 181 individual known PSP risk variants were associated with disease status in this subgroup either 182 (Fig. 1). Our results indicate that the movement disorder recruited nR-PSP patients lacked an 183 enrichment not only for MAPT H1 haplotypes but also for other known PSP risk factors. Subgroup-specific association of each individual risk variant constituting the different PRSs is 184 185 available (Supplementary Tables 10-14).

186 Our data suggests two possible sources of contamination in our clinical dataset. On the one hand, 187 nR-PSP patients who do not evolve to PSP-RS, the hallmark PSP phenotype, are hard to conclusively diagnose pre-mortem¹⁸. Thus, a weaker enrichment in known genetic PSP risk 188 189 factors and, conversely, an enrichment in risk factors for other neurodegenerative diseases can be 190 somewhat expected in the nR-PSP group. On the other hand, the observed enrichment in PD genetic risk variants in the context of movement disorder units suggests the presence of a fraction 191 192 of misclassified parkinsonian PSP-like phenocopies in this clinical setting¹⁹. PSP-P patients 193 comprise up to a third of the total number of PSP patients and are particularly challenging to 194 accurately diagnose based solely on clinical symptoms²⁰. As these patients are characterized by an initial phase with PD-compatible features, a higher chance of recruitment by movement 195 disorder units rather than by memory clinics might explain our results²¹. However, a smaller risk 196 197 effect of the MAPT H1 haplotype has also been described in PSP-P subjects compared to PSP-198 RS²², which may also explain the decrease in MAPT H1 frequency we observed in the nR-PSP groups. Overall, our findings suggest that there might be room for improvement of the specificity 199 200 of the MDS criteria by increasing the diagnostic accuracy of atypical PSP phenotypes, specially 201 PSP-P. Various biomarkers are under development to further help discriminate PSP from PSP-202 like patients: Real time quaking induced conversion (RT-QuIC) techniques to discard α -synuclein 203 parkinsonian pathology, or for confirmation of 4R tauopathy are underway as CSF biomarkers, 204 and MRI parameters like the magnetic resonance parkinsonism index are showing promising 205 results in predicting PSP-RS conversion in early PSP-P subjects²¹.

206

207 6. <u>Supplementary notes: Sensitivity analysis of PSP sentinels</u>

208 Based on our previous results, we decided to run a sensitivity analysis for known PSP risk variants, based on GWS hits by Sanchez-Contreras et al¹⁵, stratifying our Stage I cases in three 209 groups of decreasing PSP certainty: histopathological PSP, PSP-RS and nR-PSP. To improve 210 comparability of the calculated estimates, we included the complete set of Stage I controls 211 212 (N=1450) in all three strata. For all tested variants, we found consistent effect directions between 213 the histopathological and PSP-RS groups (Supplementary Fig. 2). The effects in the nR-PSP group were smaller or even had opposite directions for the tested variants, except for rs242557, 214 215 the variant tagging the MAPT H1c haplotype suggesting it may similarly impact genetic 216 susceptibility to PSP-like syndromes. Finally, we decided to repeat the meta-analysis of the Stage 217 I discovery and validation datasets, this time keeping only the PSP-RS samples in the validation 218 set. After removing nR-PSP samples, the effect sizes were stronger in all PSP susceptibility 219 variants (Supplementary Table 9), showcasing the benefits of removing these samples with lower 220 diagnostic accuracy from our GWAS analysis.

221 7. <u>Supplementary notes: Enrichment analysis</u>

Enrichment analysis was performed using WebGestalt (https://www.webgestalt.org/) over-222 223 representation analysis²³. Briefly, this method evaluates the fraction of genes which constitute the 224 different gene sets that are present in the list of genes introduced, testing the significance using a 2x2 contingency table²⁴. We introduced the list of replicated genes (MAPT, MOBP, EIF2AK3, 225 226 STX6, DUSP10, SLCO1A2) and our novel NFASC gene and ran the over representation analysis 227 algorithm, enriching specifically for non-redundant gene ontology terms and using the "Affy 228 Axiom Biobank1" option as the reference gene set. Although none of the top enriched terms were 229 significant after multiple test correction (Extended Data Table 6), the term GO:0097386, 230 representing glial cell projection was borderline significant (FDR adjusted p-value = 0.06) and 231 several of the top ranked terms were related to axon ensheathment and myelination, pinpointing 232 these processes as those more represented by our list of genes.

233 8. <u>Supplementary notes: Gene co-expression network analysis.</u>

networks 234 GeneFriends Gene co-expression were generated using software (https://www.genefriends.org/)²⁵, including all interesting confirmed loci and candidates (MAPT, 235 MOBP, EIF2AK3, STX6, DUSP10, SLCO1A2, NFASC and CNTN2) using the Sequence Read 236 237 Archive (SRA) human tissue co-expression map as a reference, which comprises 20 tissues from 238 46080 RNA-seq samples. Briefly, this method first estimates correlations between each pair of 239 genes, then uses co-expression associations to construct the co-expression network, and finally 240 modules, i.e. groups of co-expressed genes are identified using clustering techniques, allowing to 241 group those genes with similar expression patterns across the different samples. The Pearson 242 correlation threshold was adjusted to 0.6 to allow us to identify the top genes co-expressed with

- 243 our main cluster, consisting of MOBP, SLCO1A2 and NFASC. We found that MARK1, as well as
- three additional lncRNAs and one pseudogene, were strongly co-expressed (R>0.6) with this gene
- cluster (Extended Data Fig. 5).

246 Supplementary Table Legends

- 247 **Supplementary Table 1.** QC summary of contributed samples by collaborating center and stage.
- 248 Supplementary Table 2. Age linear regressions results for the complete set of controls used in
- 249 PSP/DEGESCO Stage I (N=1450). Genomic coordinates correspond to the GRCh38 assembly.
- 250 Supplementary Table 3. Reported summary statistics of the variants used to construct the
- Alzheimer's Disease (AD) PRS. We used exclusively effects from stage 2 of the Bellenguez *et al.*

study¹². Genomic coordinates correspond to the GRCh38 assembly.

- 253 Supplementary Table 4. List of the variants used to construct the amyotrophic lateral sclerosis
- (ALS) PRS. These summary statistics correspond to the European ancestry GWAS from theoriginal study. Genomic coordinates correspond to the GRCh38 assembly.
- Supplementary Table 5. List of the variants used to construct the all stroke (AS) PRS. Genomic
 coordinates correspond to the GRCh38 assembly.
- 258 Supplementary Table 6. List of the variants used to construct the Parkinson's Disease (PD) PRS.
- 259 Genomic coordinates correspond to the GRCh38 assembly.
- 260 Supplementary Table 7. List of the variants used to construct the progressive supranuclear palsy


261 (PSP) PRS. Genomic coordinates correspond to the GRCh38 assembly.

- Supplementary Table 8. Estimation of the percentage of misdiagnosed clinical PSP samples classified by those with/without Richardson's Syndrome and by recruitment centre (Movement Disorder Unit/Memory Clinic) in PSP/DEGESCO Stage I. ORs were calculated fitting logistic regressions adjusted by the first four PCs and using the same set of controls in all groups (N=1450). Percentage of misdiagnosed samples was calculated based on MAPT H1 haplotype frequencies and log odds ratios. Age data represents age at death, age at onset of motor symptoms and age at last visit for histopathological PSP, clinical PSP and controls, respectively.
- Supplementary Table 9. Sensitivity analysis results for the replicated variants. We showcase the
 results obtained in the previous study and the PSP/DEGESCO meta-analysis results including and
 excluding nR-PSP samples. Models were adjusted by the first four PCs. EA, effect allele; OA,
- other allele; OR, odds ratio; P, p-value.
- Supplementary Table 10. Association in case control logistic regression of neurodegenerative
 disease PRSs with PSP in the different clinical subgroups. PRSs were calculated using all reported
- variants, and removing variants in chr17 to account for MAPT pleiotropy. Associations are
- 276 reported in the following format: OR [95%CI]; P. OR, odds ratio; PRS, polygenic risk score; AD,
- 277 Alzheimer's Disease; PD, Parkinson's Disease; ALS, amyotrofic lateral sclerosis; PSP,
- 278 progressive supranuclear palsy; AS, all stroke.
- Supplementary Table 11. Association in case control logistic regression of the individual
 variants used to construct the Alzheimer's Disease (AD) PRS with the different PSP subgroups in
 PSP/DEGESCO Stage I.

Supplementary Table 12. Association in case control logistic regression of the individual
variants used to construct the amyotrophic lateral sclerosis (ALS) PRS with the different PSP
subgroups in PSP/DEGESCO Stage I.

- 285 Supplementary Table 13. Association in case control logistic regression of the individual
- variants used to construct the all stroke (AS) PRS with the different PSP subgroups in
 PSP/DEGESCO Stage I.
- 288 Supplementary Table 14. Association in case control logistic regression of the individual
- variants used to construct the Parkinson's disease (PD) PRS with the different PSP subgroups in
- 290 PSP/DEGESCO Stage I.
- 291 Supplementary Table 15. Association in case control logistic regression of the individual
- variants used to construct the progressive supranuclear palsy (PSP) PRS with the different PSP
- subgroups in PSP/DEGESCO Stage I.

294 Supplementary Figures



295

Supplementary Fig. 1. Mean AD, PD, ALS, PSP and AS PRS in each PSP subgroup including

and excluding variants in chr17. Values were zero-centred with respect to the control group to

better reflect the increase/decrease in mean PRS in the PSP groups with respect to the controls.
OR, odds ratio; PRS, polygenic risk score; AD, Alzheimer's Disease; PD, Parkinson's Disease;

ALS, amyotrophic lateral sclerosis; PSP, progressive supranuclear palsy; AS, all stroke; ***

301 p<0.001; ** p<0.01; * p<0.05.

302

rsid	Gene		PSP group	OR [CI95%]
rs8070723	MAPT			
		⊢ = (Histopathological PSP	4.67 [3.06-7.13]
		⊢ ∎ i	PSP-RS	4.02 [2.54-6.36]
		⊢	nR-PSP	2.26 [1.49-3.43]
rs242557	MAPT			
		H	Histopathological PSP	0.76 [0.59-0.98]
		H	PSP-RS	0.82 [0.61-1.09]
		⊢ _	nR-PSP	0.82 [0.58-1.14]
rs1768208	MOBP			
			Histopathological PSP	0.85 [0.66-1.10]
			PSP-RS	0.65 [0.49-0.87]
			nR-PSP	0.73 [0.53-1.00]
rs7571971	EIF2AK3			
			Histopathological PSP	0.94 [0.72-1.22]
			PSP-RS	0.64 [0.48-0.84]
			nR-PSP	0.9 [0.65-1.26]
rs1411478	STX6		Histopathological PSP	0.88 [0.69-1.13]
			PSP-RS	0.88 [0.89-1.13]
			nR-PSP	1.09 [0.80-1.50]
rs11568563	SLCO1A2		IIK-F3F	1.09 [0.80-1.50]
1311000000	0200172		Histopathological PSP	0.47 [0.33-0.67]
			PSP-RS	0.54 [0.35-0.82]
			nR-PSP	0.93 [0.52-1.67]
rs6687758	DUSP10			0.00 [0.02]
		L	Histopathological PSP	0.81 [0.60-1.08]
		▶ 	PSP-RS	0.84 [0.60-1.17]
		F	nR-PSP	1.36 [0.88-2.12]
rs12744678	NFASC			
		H	Histopathological PSP	0.86 [0.67-1.11]
		H H	PSP-RS	0.69 [0.52-0.91]
			nR-PSP	0.97 [0.69-1.34]

Supplementary Fig. 2. Forest plot displaying effect sizes of SNPs in the histopathological
 and clinical groups (PSP-RS or nR-PSP) of PSP/DEGESCO Stage I. Models were adjusted
 by PCs1-4 and included the same set of controls (N=1450) to improve comparability. OR, odds
 ratio; CI95%, 95% confidence interval.

317 Supplementary References

- 318 1. de Rojas, I. et al. Common variants in Alzheimer's disease and risk stratification by
- polygenic risk scores. *Nature Communications* (2021) doi:10.1038/s41467-021-22491-8.
- 320 2. Moreno-Grau, S. et al. Genome-wide association analysis of dementia and its clinical
- 321 endophenotypes reveal novel loci associated with Alzheimer's disease and three causality
- 322 networks: The GR@ACE project. *Alzheimer's and Dementia* (2019)
- doi:10.1016/j.jalz.2019.06.4950.
- 324 3. Gogarten, S. M. et al. Genetic association testing using the GENESIS R/Bioconductor
- 325 package. *Bioinformatics* (2019) doi:10.1093/bioinformatics/btz567.
- 4. Das, S. *et al.* Next-generation genotype imputation service and methods. *Nat Genet* 48, 1284–1287 (2016).
- 5. Taliun, D. *et al.* Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program.
- 329 *Nature* **590**, 290–299 (2021).
- 330 6. The 1000 Genomes Project Consortium *et al.* A global reference for human genetic variation.
 331 *Nature* 526, 68–74 (2015).
- 332 7. Anderson, C. A. et al. Europe PMC Funders Group Data quality control in genetic case-
- control association studies. *Nature Protocols* (2011) doi:10.1038/nprot.2010.116.Data.
- 8. Baker, M. et al. Association of an Extended Haplotype in the Tau Gene with Progressive
- 335 Supranuclear Palsy. *Human Molecular Genetics* **8**, 711–715 (1999).
- 336 9. Gayán, J. *et al.* Genetic Structure of the Spanish Population. *BMC Genomics* 11, 326 (2010).
- 337 10. Höglinger, G. U. et al. Identification of common variants influencing risk of the
- tauopathy progressive supranuclear palsy. in *Nature Genetics* (2011). doi:10.1038/ng.859.
- 339 11. Simón-Sánchez, J. et al. Genome-wide association study reveals genetic risk underlying
- 340 Parkinson's disease. *Nat Genet* **41**, 1308–1312 (2009).
- 341 12. Bellenguez, C. et al. New insights into the genetic etiology of Alzheimer's disease and
- 342 related dementias. *Nat Genet* **54**, 412–436 (2022).

- 343 13. Nalls, M. A. *et al.* Identification of novel risk loci, causal insights, and heritable risk for
 344 Parkinson's disease: a meta-analysis of genome-wide association studies. *Lancet Neurol* 18,
- **345** 1091–1102 (2019).
- 14. van Rheenen, W. et al. Common and rare variant association analyses in amyotrophic
- 347 lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific
- 348 biology. *Nat Genet* **53**, 1636–1648 (2021).
- 349 15. Sanchez-Contreras, M. Y. et al. Replication of progressive supranuclear palsy genome-
- 350 wide association study identifies SLCO1A2 and DUSP10 as new susceptibility loci. *Mol*
- 351 *Neurodegeneration* **13**, 37 (2018).
- 352 16. Mishra, A. *et al.* Stroke genetics informs drug discovery and risk prediction across
 ancestries. *Nature* 611, 115–123 (2022).
- 17. Höglinger, G. U. et al. Clinical diagnosis of progressive supranuclear palsy: The
- 355 movement disorder society criteria: MDS Clinical Diagnostic Criteria for PSP. Mov Disord.

356 32, 853–864 (2017).

- 18. Respondek, G. et al. Accuracy of the national institute for neurological disorders and
- 358 stroke/society for progressive supranuclear palsy and neuroprotection and natural history in
- 359 Parkinson plus syndromes criteria for the diagnosis of progressive supranuclear palsy.
- 360 *Movement Disorders* 28, 504–509 (2013).
- 361 19. Boxer, A. L. *et al.* Advances in progressive supranuclear palsy: new diagnostic criteria,
- biomarkers, and therapeutic approaches. *The Lancet Neurology* **16**, 552–563 (2017).
- 363 20. Alster, P., Madetko, N., Koziorowski, D. & Friedman, A. Progressive Supranuclear
- 364 Palsy—Parkinsonism Predominant (PSP-P)—A Clinical Challenge at the Boundaries of PSP
- and Parkinson's Disease (PD). Front. Neurol. 11, 180 (2020).
- 366 21. Coughlin, D. G. & Litvan, I. Progressive supranuclear palsy: Advances in diagnosis and
- 367 management. *Parkinsonism Relat Disord* **73**, 105–116 (2020).
- 368 22. Williams, D. R. et al. Characteristics of two distinct clinical phenotypes in
- 369 pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-
- 370 parkinsonism. *Brain* **128**, 1247–1258 (2005).

- 371 23. Wang, J., Vasaikar, S., Shi, Z., Greer, M. & Zhang, B. WebGestalt 2017: a more
- 372 comprehensive, powerful, flexible and interactive gene set enrichment analysis toolkit.
- 373 *Nucleic Acids Research* **45**, W130–W137 (2017).
- 24. Khatri, P., Sirota, M. & Butte, A. J. Ten Years of Pathway Analysis: Current
- 375 Approaches and Outstanding Challenges. *PLoS Comput Biol* **8**, e1002375 (2012).
- 376 25. Raina, P. et al. GeneFriends: gene co-expression databases and tools for humans and
- 377 model organisms. *Nucleic Acids Research* **51**, D145–D158 (2023).
- 378
- 379
- 380